<DOC>
	<DOCNO>NCT00653835</DOCNO>
	<brief_summary>This study ass whether co-administration ezetimibe 10 mg simvastatin 20 mg effective treatment simvastatin 20 mg alone reduce LDL-C concentration administer 6 week .</brief_summary>
	<brief_title>Ezetimibe Plus Simvastatin Versus Simvastatin Untreated Subjects With High Cholesterol ( P03435 )</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<criteria>&gt; =18 year &lt; = 75 year age LDLC concentration &gt; = 3.3 mmol/L ( 130 mg/dL ) &lt; = 4.9 mmol/L ( 190 mg/dL ) baseline . Triglyceride concentration &lt; 3.99 mmol/L ( 350 mg/dL ) baseline . Documented coronary heart disease ( CHD ) , include one follow feature : document stable angina ( evidence ischemia exercise test ) ; history MI ; history PCI ( primarily PTCA without stent replacement ) ; symptomatic peripheral vascular disease ; document history atherothrombotic cerebrovascular disease ; and/or document history nonQ wave MI . Stable weight history least 4 week prior entry study baseline . Female subject childbearing potential must use acceptable method birth control surgically sterilize . Body mass index ( BMI ) &gt; =35 kg/m^2 baseline . Subjects whose liver transaminases ( ALT , AST ) &gt; 1.5 time upper limit normal active liver disease baseline . Subjects evidence current myopathy ( include subject CK &gt; 1.5 time upper limit normal ) baseline . Subjects clinical laboratory test ( CBC , blood chemistry , urinalysis ) outside normal range clinically acceptable investigator baseline . Subjects Type II diabetes mellitus poorly control ( HbA1c &gt; 9 % ) newly diagnose ( within 3 month ) change antidiabetic therapy within 3 month baseline . Subjects Type I diabetes mellitus stable insulin regimen 3 month prior baseline , recent history repeat hypoglycaemia unstable glycaemic control . Subjects know hypersensitivity HMGCoA reductase inhibitor . Female subject consume &gt; 14 unit male subject consume &gt; 21 unit alcohol per week . Female subject pregnant breast feeding . Subjects observed designate washout period prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>